Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Stereotaktisk boost och kortvarig strålbehandling för orofarynxcancer (SHORT-OPC)

Stereotaktisk boost- och korttidsstrålningsterapi för HPV-associerad OroPharynx-cancerstudie: en randomiserad multicentrisk fas II-studie

This is a randomized clinical trial comparing the outcomes of short-course chemoradiation consisting in stereotactic boost to the gross tumor and de-esclalated chemoradiation to the elective neck in human papilloma associated oropharynx cancer vs. the current standard 7-week course chemoradiation.

Studieöversikt

Detaljerad beskrivning

Concurrent platinum-based chemoradiation remains the standard of care in locally advanced head and neck cancer. The current standard radiation regimen consists in a 7-week course of conventionally fractionated radiotherapy to the gross tumor volume (GTV), along with bilateral prophylactic neck irradiation to an elective dose of ~ 50 Gy in 2 Gy per fraction. In addition to being cumbersome, the current protracted daily radiation course is associated with high rates of acute and late toxicities and significant deterioration of patients' quality of life. In the light of the remarkably improved prognosis of the distinct subgroup of HPV-OPC, there is growing interest for treatment de-intensification strategies in contemporaneous OPC cohorts.

Stereotactic ablative radiotherapy (SABR) allows for ultra-precise delivery of ablative radiation dose over a small number of fractions, by combining sharp dose gradients with use of optimal image guidance. The increased conformity and reduced margins used in SABR can substantially reduce the dose to surrounding organs at risk and could therefore reduce toxicity. In addition, previous work has shown that an elective dose of 40 Gy in 2 Gy per fraction, in conjunction with chemotherapy, is sufficient for microscopic sterilisation of cancer cells and can translate into a reduction of toxicities.

The goal of this trial is to compare the efficacy and safety of short-course chemoradiation consisting in stereotactic boost to the gross tumor of 14 Gy in 2 fractions followed by de-esclalated chemoradiation (40 Gy in 20 fractions and concurrent 2 cycles of Cisplatin 100mg/m2) in human papilloma associated oropharynx cancer vs. the current standard 7-week course chemoradiation (70 Gy in 33 fractions with 2-3 cycles of Cisplatin 100mg/m2).

This is an open label randomized phase III non inferiority trial. Patients will be randomized using a 1:1 ratio between the standard and the experimental arm and will be stratified by tumor stage and use of concurrent chemotherapy.

Studietyp

Interventionell

Inskrivning (Beräknad)

360

Fas

  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • Texas
      • Houston, Texas, Förenta staterna, 77030
        • Rekrytering
        • University of Texas MD Anderson Cancer Center
        • Kontakt:
        • Huvudutredare:
          • Jack Phan, MD PhD
    • British Columbia
      • Kelowna, British Columbia, Kanada, V1Y 5L3
    • Ontario
      • London, Ontario, Kanada
        • Rekrytering
        • London Health Sciences Center
        • Kontakt:
    • Quebec
      • Montreal, Quebec, Kanada, H2X 1R6
        • Rekrytering
        • Centre Hospitalier de l'Université de Montréal
        • Kontakt:
        • Huvudutredare:
          • Houda Bahig
        • Underutredare:
          • Phuc-Félix Nguyen-Tan

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Age ≥18 years
  • Ability to provide written informed consent.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
  • Biopsy proven diagnosis of squamous cell carcinoma of the oropharynx.
  • Positive for HPV by p16 immunohistochemistry (IHC) or HPV in-situ hybridization (ISH)
  • Clinical stage T1-3, N1 M0 (Stage I-II) as per AJCC 8th edition.
  • Primary tumor < 30 cc
  • Planned for curative chemoradiation
  • For females of child-bearing age, a negative pregnancy test

Exclusion Criteria:

  • Clinical N3 classification, as per AJCC 8th edition
  • Clinically overt extranodal extension (ENE). As per AJCC 8th edition, clinically overt ENE is defined as invasion of the skin, infiltration of musculature/fixation to adjacent structures on clinical examination, cranial nerve, brachial plexus, sympathetic trunk or phrenic nerve invasion with dysfunction).
  • Previous irradiation of the head and neck region
  • Previous surgery of the HNC region (except for incisional or excisional biopsies)
  • Pregnancy or breastfeeding
  • Connective tissue disease
  • Any medical condition that could, in the opinion of the investigator, prevent follow-up after radiotherapy.
  • Non-Cisplatin concurrent chemotherapy
  • Prior induction chemotherapy

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: SABR boost and de-escalated chemoradiation

SABR boost of 14 Gy in 2 fractions to the GTV, immediately followed by de-escalated chemoradiation. De-escalated chemoradiation will consist in 40 Gy in 20 fractions with concurrent high dose Cisplatin (3-weekly, 100 mg/m2) for 2 cycles, aiming for a cumulative dose of 200 mg/m2.

Stereotactic body radiotherapy boost to the gross tumor volume to a dose of 14 Gy in 2 fractions, followed by cisplatin-based chemoradiation to a dose of 40 Gy in 20 fractions

Aktiv komparator: Standard chemoradiation

The standard arm will consist of conventionally radiation to a dose of 70 Gy in 33 fractions concurrently with high dose Cisplatin (3-weekly, 100 mg/m2) for 2-3 cycles, aiming for a cumulative dose of ≥ 200 mg/m2.

Standard Cisplatin-based chemoradiation to a dose of 70 Gy in 33 fractions

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Progression free survival
Tidsram: 2 years after the end of chemoradiation

Patient alive with no local, regional or distant recurrence at 2 years after the end of chemoradiation

2 years after the end of chemoradiation

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Subacute toxicity
Tidsram: Between 2 and 6 months after the end of chemoradiation

Rate of grade ≥ 3 subacute toxicity

Between 2 and 6 months after the end of chemoradiation
Acute toxicity
Tidsram: Less than 2 months after the end of chemoradiation

Rate of grade ≥ 3 acute toxicity

Less than 2 months after the end of chemoradiation
Late toxicity
Tidsram: Between 6 months and 5-years after the end of chemoradiation

Rate of grade ≥ 3 late toxicity

Between 6 months and 5-years after the end of chemoradiation
OS
Tidsram: At 2- and 5-years after the end of chemoradiation

Overall survival

At 2- and 5-years after the end of chemoradiation
locoregional control
Tidsram: At 2- and 5-years after the end of chemoradiation

Patient alive with locoregional control

At 2- and 5-years after the end of chemoradiation
Head and neck symptom burden
Tidsram: At baseline, and 1-, 3-, 6-, 12- months post-treatment, and yearly from years 2-5 after the end of chemoradiation

Patient-reported head and neck symptom burden as measured by the MD Anderson Symptom Inventory Head and Neck Cancer Module. The core and head and neck cancer specific symptoms are rated on a 0-10 scale to indicate the presence and severity of the symptoms. Lower scores represent better functioning and quality of life.

At baseline, and 1-, 3-, 6-, 12- months post-treatment, and yearly from years 2-5 after the end of chemoradiation
Dysphagia
Tidsram: At baseline, and 1-, 3-, 6-, 12- months post-treatment, and yearly from years 2-5 after the end of chemoradiation

Patient-reported dysphagia as measured by the MD Anderson Dysphagia Index. Overall score ranges from 0 to 100, with higher score representing better functioning and quality of life.

At baseline, and 1-, 3-, 6-, 12- months post-treatment, and yearly from years 2-5 after the end of chemoradiation
Time from treatment start to return to work
Tidsram: Measured in days and reported at 2-years post-treatment

Time from first day of treatment start to first day of return to work.

Measured in days and reported at 2-years post-treatment

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Studiestol: Phuc-Felix Nguyen-Tan, MD, Centre hospitalier de l'Université de Montréal (CHUM)
  • Huvudutredare: Jack Phan, MD PhD, M.D. Anderson Cancer Center
  • Huvudutredare: Khalil Sultanem, MD, Montreal Jewish General Hospital
  • Studiestol: Houda Bahig, MD PhD, Centre hospitalier de l'Université de Montréal (CHUM)
  • Huvudutredare: David Palma, MD PhD, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

23 februari 2020

Primärt slutförande (Beräknad)

1 december 2028

Avslutad studie (Beräknad)

1 december 2030

Studieregistreringsdatum

Först inskickad

17 november 2019

Först inskickad som uppfyllde QC-kriterierna

23 november 2019

Första postat (Faktisk)

26 november 2019

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

16 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

11 november 2026

Senast verifierad

1 juli 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera